Printer Friendly

Cell Robotics International Closes Secondary Public Offering.

ALBUQUERQUE, N.M.--(BW HealthWire)--Feb. 6, 1998--Cell Robotics International, Inc. (OTC: CRII) announced today that it has closed a secondary public offering consisting of the sale of 400,000 units at $8.25 per unit.

Each unit consists of one share of convertible preferred stock and two common stock purchase warrants exercisable to purchase common stock at a price of $2.40. Each convertible preferred share is convertible into four shares of common stock upon certain circumstances. The units will trade for 30 days and thereafter the warrants and the preferred stock comprising the unit will trade separately. The proceeds from the offering after deducting the underwriter's discount and non-accountable expenses will be $2,958,127. The managing underwriter for the offering is Paulson Investment Company, Inc. of Portland, OR.

The proceeds of the offering will be used to repay a short-term loan and to support the manufacturing, marketing, selling and distributing of the Company's new medical laser products. The Company's primary marketing and sales program will focus on the Lasette(TM), a laser finger perforator for capillary blood sampling for testing glucose. The Lasette has received clearance from the United States Food & Drug Administration (FDA) for use in glucose testing by adults, including diabetics, in clinical settings.

Cell Robotics International, Inc., also manufactures, markets, and distributes scientific and medical laser devices. These devices include the FDA-cleared RevitaLase(TM), an Erbium:YAG laser for use in dermatological applications, the In Vitro Fertilization (IVF) Workstation(TM) for use in improving the success rate of IVF procedures, and the Cell Robotics Workstation, a research instrument which incorporates the LaserTweezers and LaserScissors for manipulating and cutting cells and chromosomes.

CRII's President and CEO, Dr. Ronald K. Lohrding, will be speaking at the Red Chip Review's San Francisco Investor Conference, February 12, 1998 at 3:00 PM at the San Francisco airport Clarion Hotel.

Additional information is available on the Cell Robotics Web Site at http://www.cellrobotics.com/cell, by e-mail at crii@cellrobotics.com, or by telephone at 505/343-1131.

CONTACT: Edda Brown or Sean Collins

Richmont Consulting International

213/658-8088

or

Craig Rogers

Vice President for Investor Relations

719/590-1793
COPYRIGHT 1998 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1998, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 6, 1998
Words:360
Previous Article:Acktion Corporation Company Announcement.
Next Article:Nations Government Income Term Trust 2003, Inc.; Dividend Declaration.
Topics:


Related Articles
Rebif trial disappointing for secondary-progressive MS.
Cell Robotics' CEO Interviewed by WallStreetReporter.com About Diabetic Laser.
Robotic Work Cells Boost Lost Foam Foundry's Productivity by 100%.
Cell Robotics Announces New Executive Appointments.
Needlestick Safety Alliance Formed by Six Industry Leaders.
Integrated Blow Molding Cells Use Robots.
3COM TO ACQUIRE U.S. ROBOTICS : $6.6 BILLION DEAL WILL MERGE 2 LEADERS IN COMPUTER NETWORKING.
Brains & brawn: new robots are handier than ever: at NPE, the news in robots was bigger payloads, longer reach, more axes of motion, and smarter...
Finishing off your casting.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters